Filler Product

Phase 2Biologic

JJohns Hopkins University

Filler Product is one of 5 biologic programs targeting Skin. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SkinRecruiting

SkinPhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Skin

#DrugCompanyPhaseTrials

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 1

1 2

Litifilimab

Biogen

Phase 1

1 3

Filler Product

JJohns Hopkins University

Phase 2

1 4

Na-ASP-2 Hookworm Vaccine

AAlbert B. Sabin Vaccine Institute

Preclinical

1 5

Chlorhexidine-Alcohol

WWashington University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Skin

NCT01964859

Clinical

Trials by Indication[1]

Skin1 trial

Feasibility Study for Fibroblast Autologous Skin Grafts

Recruiting·JJohns Hopkins University·Phase 2·NCT01964859·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Filler Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Filler Product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Filler Product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: JJohns Hopkins University

Filler Product

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Skin1 trial

References

Drug Info

Quick Facts

Related News